Advanced search
Publication Cover
Expert Review of Hematology Volume 5, 2012 - Issue 2
Submit an article Journal homepage
102
Views
19
CrossRef citations to date
0
Altmetric
Reviews

Treating venous thromboembolism in patients with cancer

Caroline Piatek Jane Anne Nohl Division of Hematology, Department of soft return Medicine, University of Southern soft return California – Keck School of Medicine, Los Angeles, CA 90033, USA
,
Casey L O'Connell Jane Anne Nohl Division of Hematology, Department of soft return Medicine, University of Southern soft return California – Keck School of Medicine, Los Angeles, CA 90033, USA. [email protected]
&
Howard A Liebman Jane Anne Nohl Division of Hematology, Department of soft return Medicine, University of Southern soft return California – Keck School of Medicine, Los Angeles, CA 90033, USA
Pages 201-209 | Published online: 10 Jan 2014

References

  • Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am. J. Med. 119(1), 60–68 (2006).
  • Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol. 24, 484–490 (2006).
  • Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 5, 632–634 (2007).
  • Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100, 3484–3488 (2002).
  • Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846–1850 (2000).
  • Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 160, 809–815 (2000).
  • Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br. J. Haematol. 128, 291–302 (2005).
  • Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166, 458–464 (2006).
  • Alcalay A, Wun T, Khatri V et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J. Clin. Oncol. 24, 1112–1118 (2006).
  • Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J. Clin. Oncol. 25, 70–76 (2007).
  • Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol. Oncol. 105, 784–790 (2007).
  • Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb. Haemost. 4, 529–535 (2006).
  • Chew, HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J. Thromb. Haemost. 6, 601–608 (2008).
  • Agnelli G, Bolis G, Capussotti L et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS Project. Ann. Surg. 243, 89–95 (2006).
  • Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 106, 6–12 (2001).
  • Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb. Haemost. 87, 575–579 (2002).
  • Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110, 2339–2346 (2007).
  • Cronin-Fenton DP, Sondergaard F, Pedersen LA et al. Hospitalization for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br. J. Cancer 103(7), 947–953 (2010).
  • Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J. Thromb. Haemost. 9, 653–663 (2011).
  • Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. 12, 991–995 (2001).
  • Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol. 126, 715–721 (2004).
  • Zangari M, Fink LM, Elice F et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J. Clin. Oncol. 27(29), 4865–4873 (2009).
  • Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123–2132 (2007).
  • Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133–2142 (2007).
  • Lyman G, Khorana A, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490–5505 (2007).
  • Levine M, Hirsh J, Gent M et al. Doubleblind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343, 886–889 (1994).
  • Haas SK, Kakka AK, Kemkes-Matthes B et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer: results of the TOPIC Studies. J. Thromb. Haemost. 3(Suppl. 1), OR059 (2005).
  • Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb. Haemost. 94, 867–871 (2005).
  • Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N. Engl. J. Med. 336, 1506–1511 (1997).
  • Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann. Surg. 208, 227–240 (1988).
  • Kabbinavar F, Hurwitz HI, Fehrenbacher L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).
  • Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer. Inst. 99, 1232–1239 (2007).
  • Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. JAMA 300(19), 2277–2285 (2008).
  • Ranpura V, Hapani S, Chuang J et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 49, 287–297 (2010).
  • Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan- and bevacizumab-based therapy. J. Clin. Oncol. 23, 2574–2576 (2005).
  • Hurwitz HI, Saltz LB, Van Cutsem E et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized Phase II and III studies. J. Clin. Oncol. 29(13), 1757–1764 (2011).
  • Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10), 4902–4906 (2008).
  • Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104, 2822–2829 (2005).
  • Ay C, Dunkler D, Marosi C et al. Prediction of venous thromboembolism in cancer patients. Blood 116, 5377–5282 (2010).
  • Chen M, Geng JG. P-Selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch. Immunol. Ther. Exp. (Warsz) 54, 75–84 (2006).
  • Ay C, Simanek R, Vormittag R et al. High plasma levels of soluble P-Selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7), 2703–2708 (2008).
  • Ay C, Vormittag R, Dunkler D et al. d-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J. Clin. Oncol. 27(25), 4124–4129 (2009).
  • Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146–153 (2003).
  • Hull RD, Pineo GF, Brant RF et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am. J. Med. 119, 1062–1072 (2006).
  • Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch. Intern. Med. 162, 1729–1735 (2002).
  • Deitcher SR, Kessler CM, Merli G et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin. Appl. Thromb. Hemost. 12, 389–396 (2006).
  • Lopez-Beret P, Orgaz A, Fontcuberta J et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J. Vasc. Surg. 33, 77–90 (2001).
  • Louzada ML, Majeed H, Wells PS. Efficacy of low molecular weight heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb. Res. 123(6), 837–844 (2009).
  • Akl EA, Vasireddi SR, Gunukula S et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev 6, CD006649 (2011).
  • Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics 24, 593–607 (2006).
  • Geerts HW, Bergqvist D, Pineo FG et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 381S–453S (2008).
  • Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J. Thromb. Haemost. 7, 760–765 (2009).
  • Tagawa S, Weitz IC, O’Connell CL et al. Tinzaparin is effective and safe for the treatment and secondary prophylaxis in cancer patients with VTE. Blood 116, 1104 (2010).
  • Monreal M, Falga, C, Valle R et al. Venous thromboembolism in patients with renal insufficiency: Findings from the RIETE registry. Am. J. Med. 119(12), 1073–1079 (2006).
  • Lim W, Dentali F, Eikelboom JW et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann. Intern. Med. 144, 673–684 (2006).
  • Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch. Intern. Med. 162, 2605–2609 (2002).
  • Grand’Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am. J. Cardiovasc. Drugs 5, 291–305 (2005).
  • Douketis J, Cook D, Meade M et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: The DIRECT study. Arch. Intern. Med. 168(16), 1805–1812 (2008).
  • Leizorovicz A, Siguret V, Mottier D. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS). Thromb. Res. 128(1), 27–34 (2011).
  • Auer RC, Schulman AR, Tuorto S et al. Use of helical CT is associated with an increased incidence of postoperative pulmonary emboli in cancer patients with no change in the number of fatal pulmonary emboli. J. Am. Coll. Surg. 208, 871–878 (2009).
  • DeMonaco NA, Dang Q, Kapoor WN, Ragni MV. Pulmonary embolism incidence is increasing with use of spiral computed tomography. Am. J. Med. 121, 611–617 (2008).
  • Dentali F, Ageno W, Becattini C et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb. Res. 125, 518–522 (2010).
  • O’Connell CL, Boswell WD, Duddalwar V et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J. Clin. Oncol. 24(30), 4928–4932 (2006).
  • O’Connell C, Razavi P, Liebman H. Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism. J. Clin. Oncol. 29(31), 4208–4209 (2011).
  • den Exter PL, Hooijer J, Dekkers OM et al. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J. Clin. Oncol. 29, 2405–2409 (2011).
  • Donato AA, Khoche S, Santora J, Wagner B. Clinical outcomes in patients with isolated subsegmental pulmonary emboli diagnosed by multidetector CT pulmonary angiography. Thromb. Res. 126(4), e266–e270 (2010).
  • O’Connell C, Razavi P, Ghalichi M et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging MDCT scanning. J. Thromb. Haemost. 9(2), 305–311 (2011).
  • Carrier M, Kimpton M, Le Gal G et al. The management of a sub-segmental pulmonary embolism: a cross-sectional survey of Canadian thrombosis physicians. J. Thromb. Haemost. 9(7), 1412–1415 (2011).
  • Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 454S–545S (2008).
  • Maiuri F, D’Andrea F, Gallicchio B, Carandente M. Intracranial hemorrhages in metastatic brain tumors. J. Neurosurg. Sci. 29, 37–41 (1985).
  • Perry JR. Julian JA. Laperriere NJ et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin prophylaxis in patients with newly diagnosed glioma. J. Thromb. Haemost. 8(9), 1959–1965 (2010).
  • Schrader B, Barth H, Lang EW et al. Spontaneous intracranial hematomas caused by neoplasms. Acta Neurochir. 142, 979–985 (2000).
  • Kondziolka D, Bernstein M, Resch L et al. Significance of hemorrhage into brain tumors: clinicopathological study. J. Neurosurg. 67, 852–857 (1987).
  • So W, Hugenholtz, Richard MT. Complications of anticoagulant therapy in patients with known central nervous system lesions. Can. J. Surg. 26(2), 181–183 (1983).
  • Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J. Clin. Oncol. 24, 1310–1318 (2006).
  • Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 112, e28–e32 (2005).
  • Agnelli G, Becattini C. Acute pulmonary embolism. N. Engl. J. Med. 363, 266–274 (2010).
  • Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 113, 577–582 (2006).
  • Decousus H, Leizorovicz A, Parent F et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis: Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N. Engl. J. Med. 338, 409–415 (1998).
  • Agnelli G. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. J. Clin. Oncol. 29(Suppl.), LBA9014 (2011).
  • Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 10, 943–949 (2009).
  • Riess H, Pelzer U, Opitz M et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial. J. Clin. Oncol. 28 (Suppl.15), 4033 (2010).
  • Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110, 1149–1161 (2007).
  • Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J. Clin. Oncol. 27(29), 4902–4911 (2009).
  • Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J. Thromb. Haemost. 8, 1223–1229 (2010).
  • Levine MN, Gu C, Liebman HA et al. A randomized Phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J. Thromb. Haemost. doi: 10.1111/j.1538-7836.2012.04693.x. (2012) (Epub ahead of print).
  • Cohen AT, Spiro TE, Büller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J. Thromb. Thrombolysis 31, 407–416 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.